A Novel Family of Anticoagulants from Ixodes scapularis
A Novel Family of Anticoagulants from Ixodes scapularis
批准号:
6645242
负责人:
Michel Ledizet
金额:
$13.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-22 至 2004-08-31
关键词:
Drosophilidae Escherichia coli Ixodes anticoagulants blood coagulation coagulation factor X complementary DNA computer assisted sequence analysis drug discovery /isolation endopeptidases gene expression information systems inhibitor /antagonist physical model posttranslational modifications protease inhibitor protein structure function recombinant proteins salivary glands
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall objective of this proposal is to evaluate the anticoagulant properties of a family of novel tick salivary proteins Ixodes scapularis, the black-legged tick, circumvents host hemostatic mechanisms as it engorges on vertebrate hosts. This tick's saliva contains potent anticoagulants, including a Factor Xa inhibitor. Purified salivary proteins with anticoagulant activity were subjected to N-terminal sequencing. A corresponding tick salivary cDNA was cloned that encoded a 96 kDa protein, designated Salp9A. This protein is homologous to Salp14, which we previously identified by immunoscreening a tick salivary gland cDNA expression library. Additional protein and cDNA sequencing indicate that I scapularis salivary glands express at least ten different Salp14-related proteins. We expressed and purified recombinant Salp14, and found that it inhibits coagulation and Factor Xa. These data suggest that we have discovered a new family of anticoagulants. In Phase I experiments we will obtain full-length cDNAs encoding selected Salp14 family members. Recombinant proteins will be expressed from these cDNAs. The recombinant proteins will be compared to partially purified salivary anticoagulants in anticoagulant and protease inhibition assays. These studies will relate structure and function, and provide a rational basis for selecting anticoagulant molecules for Phase II animal studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vaccination against Zika virus infection using mosquito NeSt1 protein
-
批准号:10194371
-
项目类别:
-
资助金额:$29.39万
-
财政年份:2020
-
负责人:Michel Ledizet
-
依托单位:
Vaccination against Zika virus infection using mosquito NeSt1 protein
-
批准号:10081573
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2020
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10403621
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10082042
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
An antigen-detection assay to diagnose Babesia microti infection
-
批准号:10200003
-
项目类别:
-
资助金额:$69.21万
-
财政年份:2018
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8876556
-
项目类别:
-
资助金额:$82.57万
-
财政年份:2014
-
负责人:Michel Ledizet
-
依托单位:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
-
批准号:8455815
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2013
-
负责人:Michel Ledizet
-
依托单位:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
-
批准号:8601286
-
项目类别:
-
资助金额:$29.57万
-
财政年份:2013
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8782201
-
项目类别:
-
资助金额:$82.94万
-
财政年份:2012
-
负责人:Michel Ledizet
-
依托单位:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
-
批准号:8315248
-
项目类别:
-
资助金额:$29.03万
-
财政年份:2012
-
负责人:Michel Ledizet
-
依托单位:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
-
批准号:8715103
-
项目类别:
-
资助金额:$88.34万
-
财政年份:2010
-
负责人:Michel Ledizet
-
依托单位:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
-
批准号:7802551
-
项目类别:
-
资助金额:$27.85万
-
财政年份:2010
-
负责人:Michel Ledizet
-
依托单位:
Nanoparticle-based vaccines against flaviviruses
-
批准号:7647312
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:Michel Ledizet
-
依托单位:
Nanoparticle-based vaccines against flaviviruses
-
批准号:7537716
-
项目类别:
-
资助金额:$29.14万
-
财政年份:2008
-
负责人:Michel Ledizet
-
依托单位:
Lyme Disease Diagnostics Using In Vivo Expressed Borrelia Burgdorferi Antigens
-
批准号:7404707
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2008
-
负责人:Michel Ledizet
-
依托单位:
Antivirals Targeting Flavivirus Envelope Proteins
-
批准号:7110867
-
项目类别:
-
资助金额:$49.37万
-
财政年份:2006
-
负责人:Michel Ledizet
-
依托单位:
Antivirals Targeting Flavivirus Envelope Proteins
-
批准号:7281246
-
项目类别:
-
资助金额:$50.46万
-
财政年份:2006
-
负责人:Michel Ledizet
-
依托单位:
Therapeutic Activity of a Novel Tick Immunosuppressant
-
批准号:6645231
-
项目类别:
-
资助金额:$9.97万
-
财政年份:2003
-
负责人:Michel Ledizet
-
依托单位:
Vaccination Against Ixodes scapularis Tick Bites
-
批准号:6655558
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2001
-
负责人:Michel Ledizet
-
依托单位:
Vaccination Against Ixodes scapularis Tick Bites
-
批准号:6550847
-
项目类别:
-
资助金额:$37.42万
-
财政年份:2001
-
负责人:Michel Ledizet
-
依托单位:
国内基金
海外基金
登录
查看更多内容
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
-
批准号:32302245
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:潘寒姁
-
依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
-
批准号:82371775
-
项目类别:面上项目
-
资助金额:46万元
-
批准年份:2023
-
负责人:朱慧媛
-
依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
-
批准号:31871817
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2018
-
负责人:孙爱东
-
依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
-
批准号:81873549
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:刘玉兰
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的分子机制
-
批准号:31571933
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:廖小军
-
依托单位:
超高压诱导牛肉中Escherichia coli O157:H7亚致死损伤及其修复研究
-
批准号:31371861
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:江芸
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的机制
-
批准号:31371845
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:廖小军
-
依托单位:
高密度二氧化碳致死Escherichia coli的相关蛋白质确证及其结构变化研究
-
批准号:31171774
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2011
-
负责人:张德权
-
依托单位: